Ovid Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Ovid Therapeutics
OVID Stock  USD 0.46  0.01  2.13%   
Ovid Therapeutics financial statements provide useful quarterly and yearly information to potential Ovid Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ovid Therapeutics financial statements helps investors assess Ovid Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ovid Therapeutics' valuation are summarized below:
Gross Profit
566 K
Market Capitalization
33.1 M
Enterprise Value Revenue
37.7892
Revenue
566 K
Earnings Share
(0.37)
There are over one hundred nineteen available trending fundamental ratios for Ovid Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Ovid Therapeutics' recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 19, 2025, Market Cap is expected to decline to about 62.9 M. In addition to that, Enterprise Value is expected to decline to about 39.2 M

Ovid Therapeutics Total Revenue

537,700

Check Ovid Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ovid Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Selling General Administrative of 23 M or Total Revenue of 537.7 K, as well as many indicators such as Price To Sales Ratio of 127, Dividend Yield of 0.0 or PTB Ratio of 0.92. Ovid financial statements analysis is a perfect complement when working with Ovid Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Ovid Therapeutics Correlation against competitors.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

Ovid Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets100.8 M92.2 M70.5 M
Slightly volatile
Total Current Liabilities9.7 M10.5 M6.7 M
Slightly volatile
Total Stockholder Equity82.6 M68.2 M58 M
Slightly volatile
Net Tangible Assets81.7 M152.1 M65.8 M
Slightly volatile
Accounts Payable3.2 M3.2 M2.2 M
Slightly volatile
Cash25 M26.3 M48.7 M
Slightly volatile
Common Stock Shares Outstanding47.1 M70.9 M34.9 M
Slightly volatile
Total Liabilities18.2 M23.9 M12.5 M
Slightly volatile
Total Current Assets90.2 M55.9 M63.3 M
Slightly volatile
Intangible Assets235.2 K210.4 K162.1 K
Slightly volatile
Common Stock50.2 K71 K39.5 K
Slightly volatile
Property Plant Equipment1.4 M1.3 M353.2 K
Slightly volatile
Other Current Liabilities6.6 M6 M4.7 M
Slightly volatile
Property Plant And Equipment Net13.9 M13.2 M3.7 M
Slightly volatile
Non Current Assets Total38 M36.2 M9 M
Slightly volatile
Non Currrent Assets Other1.5 M2 M933.2 K
Slightly volatile
Cash And Short Term Investments96.2 M53.1 M82.6 M
Slightly volatile
Net Receivables403.4 K300.4 K270 K
Slightly volatile
Common Stock Total Equity46.7 K81 K36.7 K
Slightly volatile
Liabilities And Stockholders Equity110.4 M92.2 M91.6 M
Slightly volatile
Other Current Assets2.3 M2.9 M1.5 M
Slightly volatile
Other Stockholder Equity290 M372.5 M208.4 M
Slightly volatile
Property Plant And Equipment Gross15.4 M14.6 M4 M
Slightly volatile
Capital Surpluse312.6 M411.4 M254.8 M
Slightly volatile
Net Invested Capital96.8 M68.2 M86.5 M
Pretty Stable
Net Working Capital43.1 M45.4 M81.5 M
Very volatile
Capital Stock67.2 K71 K43.3 K
Slightly volatile
Other Liabilities12.4 M11.8 M4.2 M
Slightly volatile
Non Current Liabilities Other36.2 M34.5 M10.2 M
Slightly volatile
Current Deferred Revenue1.8 M2 M2.2 M
Slightly volatile
Short and Long Term Debt Total1.3 M1.3 M14.6 M
Slightly volatile
Short Term Debt1.1 M1.3 M666.6 K
Slightly volatile

Ovid Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative23 M25.7 M15.9 M
Slightly volatile
Research Development34.3 M36.8 M23.6 M
Slightly volatile
Total Operating Expenses57.3 M62.5 M39.5 M
Slightly volatile
Interest Income4.1 M3.9 M1.9 M
Slightly volatile
Depreciation And Amortization1.9 M1.8 M493.1 K
Slightly volatile
Other Operating Expenses63 M62.5 M43.8 M
Slightly volatile
Net Interest Income2 M3.9 M1.8 M
Slightly volatile
Reconciled Depreciation639.5 K613 K365.8 K
Slightly volatile
Non Operating Income Net Other957.3 K1.6 M723.3 K
Slightly volatile
Selling And Marketing Expenses581653712
Slightly volatile

Ovid Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock154.5 K162.6 K20.2 M
Very volatile
Net Borrowings64 K72 K78.5 K
Slightly volatile
Depreciation468.3 K613 K322.5 K
Slightly volatile
Capital Expenditures67.5 K71 K198.3 K
Slightly volatile
End Period Cash Flow26.8 M28.2 M44 M
Slightly volatile
Change To Netincome8.9 M7.5 M6 M
Slightly volatile
Stock Based Compensation6.2 M6.3 M4.4 M
Slightly volatile
Begin Period Cash Flow27.5 M29 M42.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12711764.4058
Slightly volatile
PTB Ratio0.920.97045.36
Slightly volatile
Days Sales Outstanding3.283.694.024
Slightly volatile
Book Value Per Share0.910.96221.6906
Very volatile
Average Payables2.1 M3.2 M2.3 M
Slightly volatile
Stock Based Compensation To Revenue11.6411.08833.2672
Slightly volatile
Capex To Depreciation0.110.11581.2137
Pretty Stable
PB Ratio0.920.97045.36
Slightly volatile
EV To Sales10372.861149.6911
Slightly volatile
Inventory Turnover0.180.210.2281
Slightly volatile
Days Of Inventory On Hand1.3 K1.4 K1.5 K
Slightly volatile
Payables Turnover0.670.640.2792
Slightly volatile
Sales General And Administrative To Revenue23.8345.378112.3147
Slightly volatile
Average Inventory97.1 K109.2 K119.1 K
Slightly volatile
Research And Ddevelopement To Revenue68.2164.959417.3782
Slightly volatile
Capex To Revenue0.230.12540.1245
Slightly volatile
Cash Per Share0.710.74851.8414
Very volatile
Days Payables Outstanding5645939.8 K
Slightly volatile
Income Quality2.222.11690.8859
Slightly volatile
Intangibles To Total Assets0.00210.00110.002
Pretty Stable
Current Ratio5.055.316520.5509
Slightly volatile
Tangible Book Value Per Share0.910.96221.6871
Very volatile
Receivables Turnover71.280.187.3332
Slightly volatile
Shareholders Equity Per Share0.910.96221.6906
Very volatile
Debt To Equity0.01860.01960.1153
Slightly volatile
Capex Per Share0.0010.0010.0044
Slightly volatile
Graham Net Net0.390.41091.5976
Very volatile
Average Receivables60.6 K63.8 K155.1 K
Pretty Stable
Revenue Per Share0.00760.0080.3441
Very volatile
Interest Debt Per Share0.01790.01880.2072
Slightly volatile
Debt To Assets0.01380.01450.0952
Slightly volatile
Graham Number8.369.410.2494
Slightly volatile
Operating Cycle4.484.72688
Slightly volatile
Price Book Value Ratio0.920.97045.36
Slightly volatile
Days Of Payables Outstanding5645939.8 K
Slightly volatile
Ebt Per Ebit0.410.42710.9146
Slightly volatile
Company Equity Multiplier0.981.35091.1662
Slightly volatile
Total Debt To Capitalization0.01820.01920.1023
Slightly volatile
Debt Equity Ratio0.01860.01960.1153
Slightly volatile
Quick Ratio5.055.316520.5468
Slightly volatile
Net Income Per E B T1.081.090.9909
Slightly volatile
Cash Ratio2.372.499619.4029
Slightly volatile
Days Of Inventory Outstanding1.3 K1.4 K1.5 K
Slightly volatile
Days Of Sales Outstanding3.283.694.024
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00131.0134
Slightly volatile
Price To Book Ratio0.920.97045.36
Slightly volatile
Fixed Asset Turnover0.04060.0428118
Very volatile
Debt Ratio0.01380.01450.0952
Slightly volatile
Price Sales Ratio12711764.4058
Slightly volatile
Asset Turnover0.00580.00610.1827
Very volatile
Gross Profit Margin0.06450.07260.0791
Slightly volatile
Price Fair Value0.920.97045.36
Slightly volatile

Ovid Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap62.9 M66.2 M126.5 M
Pretty Stable
Enterprise Value39.2 M41.2 M80 M
Very volatile

Ovid Fundamental Market Drivers

Forward Price Earnings1.7918
Cash And Short Term Investments53.1 M

Ovid Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ovid Therapeutics Financial Statements

Ovid Therapeutics stakeholders use historical fundamental indicators, such as Ovid Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ovid Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ovid Therapeutics' assets and liabilities are reflected in the revenues and expenses on Ovid Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ovid Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2 M1.8 M
Total Revenue566 K537.7 K
Cost Of Revenue1.8 M1.9 M
Stock Based Compensation To Revenue 11.09  11.64 
Sales General And Administrative To Revenue 45.38  23.83 
Research And Ddevelopement To Revenue 64.96  68.21 
Capex To Revenue 0.13  0.23 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(109.34)(114.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:
How To Invest In Ovid
Details
Is Ovid Stock a good investment?
Details
What is Ovid Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ovid Therapeutics Correlation against competitors.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
0.008
Quarterly Revenue Growth
(0.47)
Return On Assets
(0.31)
Return On Equity
(0.34)
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY